Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Systematic Review of Randomized Controlled Trials of Exercise Interventions Using Digital Activity Trackers in Patients With Cancer.

Schaffer K, Panneerselvam N, Loh KP, Herrmann R, Kleckner IR, Dunne RF, Lin PJ, Heckler CE, Gerbino N, Bruckner LB, Storozynsky E, Ky B, Baran A, Mohile SG, Mustian KM, Fung C.

J Natl Compr Canc Netw. 2019 Jan;17(1):57-63. doi: 10.6004/jnccn.2018.7082.

PMID:
30659130
2.

Study of the wearable cardioverter defibrillator in advanced heart-failure patients (SWIFT).

Barsheshet A, Kutyifa V, Vamvouris T, Moss AJ, Biton Y, Chen L, Storozynsky E, Wan C, Szymkiewicz SJ, Goldenberg I.

J Cardiovasc Electrophysiol. 2017 Jul;28(7):778-784. doi: 10.1111/jce.13229. Epub 2017 May 29.

PMID:
28429542
3.

Effect of Gender on the Risk of Neurologic Events and Subsequent Outcomes in Patients With Left Ventricular Assist Devices.

Sherazi S, Kutyifa V, McNitt S, Papernov A, Hallinan W, Chen L, Storozynsky E, Johnson BA, Strawderman RL, Massey HT, Zareba W, Alexis JD.

Am J Cardiol. 2017 Jan 15;119(2):297-301. doi: 10.1016/j.amjcard.2016.09.032. Epub 2016 Oct 7.

PMID:
27839770
4.

The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy.

Russell RR, Alexander J, Jain D, Poornima IG, Srivastava AV, Storozynsky E, Schwartz RG.

J Nucl Cardiol. 2016 Aug;23(4):856-84. doi: 10.1007/s12350-016-0538-8. Epub 2016 Jun 1.

PMID:
27251147
5.

Multimodality assessment and treatment of chemotherapy-induced cardiotoxicity.

Storozynsky E.

Future Cardiol. 2015 Jul;11(4):421-4. doi: 10.2217/FCA.15.49. Epub 2015 Aug 4. No abstract available.

PMID:
26238563
6.

Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively.

Schwartz RG, Jain D, Storozynsky E.

J Nucl Cardiol. 2013 Jun;20(3):443-64. doi: 10.1007/s12350-013-9707-1. Review.

PMID:
23572315
7.

Review of ambulatory pulmonary artery catheterization in the management of advanced heart failure.

Mark S, Calderon-Artero P, Kakinami L, Alexis J, Chen L, Storozynsky E, Fong MW.

Congest Heart Fail. 2012 May-Jun;18(3):173-8. doi: 10.1111/j.1751-7133.2011.00268.x. Epub 2011 Nov 21.

8.

Renin inhibition for hypertension: selecting the right role for a new class of drug.

Bergset J, Storozynsky E, Bisognano JD.

Am J Ther. 2010 Mar-Apr;17(2):182-7. doi: 10.1097/MJT.0b013e31819e9e9a.

PMID:
19433972
9.

Baroreflex device therapy in the treatment of hypertension.

Uppuluri SC, Storozynsky E, Bisognano JD.

Curr Hypertens Rep. 2009 Feb;11(1):69-75.

PMID:
19146804
10.
11.
12.

IL-3-mediated enhancement of particulate antigen presentation by macrophages.

Lord EM, Yeh KY, Moran JA, Storozynsky E, Frelinger JG.

J Immunother. 1998 May;21(3):205-10.

PMID:
9610912
13.

Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes.

Wei C, Storozynsky E, McAdam AJ, Yeh KY, Tilton BR, Willis RA, Barth RK, Looney RJ, Lord EM, Frelinger JG.

Cancer Immunol Immunother. 1996 Jul;42(6):362-8.

PMID:
8830740
15.

Two populations of splenic dendritic cells detected with M342, a new monoclonal to an intracellular antigen of interdigitating dendritic cells and some B lymphocytes.

Agger R, Witmer-Pack M, Romani N, Stossel H, Swiggard WJ, Metlay JP, Storozynsky E, Freimuth P, Steinman RM.

J Leukoc Biol. 1992 Jul;52(1):34-42.

PMID:
1379295

Supplemental Content

Loading ...
Support Center